1
/
of
0
FDA FAERS Reports on IZERVAY (avacincaptad pegol) – Nov 30, 2024 to Mar 3, 2025
FDA FAERS Reports on IZERVAY (avacincaptad pegol) – Nov 30, 2024 to Mar 3, 2025
Regular price
$69.00 USD
Regular price
Sale price
$69.00 USD
Unit price
/
per
Original Request: I would like to request full reports of any and all adverse events reported to the FAERS database for IZERVAY (branded name / marketed by Astellas Pharma Inc.) or avacincaptad pegol intravitreal solution (generic name) between November 30, 2024, and March 3, 2025.
Tags: Pharma, FAERS, 2024
Tags: Pharma, FAERS, 2024
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. IMPORTANT: The FDA FOIA office operations are currently suspended. We are happy to make the request but do not know when we will receive a response. Learn more about Fast-Track Requests here.
View full details